GoldCare Townhall
The Pandemic Games: Deciphering the Future of Medical Tyranny
February 11th – 8 PM EST
00
DAYS
00
HOURS
00
MIN
00
SEC
June 20, 2025
Osteoporosis has become a billion-dollar industry—one that thrives on fear, misunderstanding, and the overuse of a single measurement: bone mineral density. Most patients never question the treatment protocols laid out for them. They’re told their bones are thinning, prescribed medications, and sent on their way. But the real story of bone health, strength, and fractures is far more complex—and rarely discussed.
The entire framework of osteoporosis treatment rests on a tool called the DEXA scan. It’s a test that estimates bone mineral density (BMD) and compares it to the average of a healthy 30-year-old woman. That comparison, called a T-score, is the basis for diagnosing both osteopenia and osteoporosis. If the number drops low enough, patients are labeled at “high risk” and told they need medication.
But here’s the catch: bone density does not equal bone strength. You can have denser bones and still suffer fractures. And you can have low bone density and live fracture-free. Yet the obsession with BMD has created a flawed system where people are pushed toward drugs that don’t always help, and sometimes harm.
In the 1990s, osteoporosis was redefined. Instead of diagnosing it after someone broke a bone (a clinical diagnosis), it became a preventive diagnosis based on DEXA scan results. This reclassification turned millions of healthy people into patients overnight. Suddenly, having a lower-than-average BMD score meant you were “at risk,” and pharma companies quickly responded with drugs to “treat” it.
One of the earliest drugs, Fosamax (a bisphosphonate), was marketed so aggressively that it reshaped the entire field. With no actual improvement in life expectancy or meaningful reduction in hip fracture rates, the drug—and others like it—became standard treatment despite major flaws.
Bisphosphonates work by disrupting normal bone turnover. They suppress the body’s natural process of breaking down and rebuilding bone tissue. On a scan, this makes bones appear denser. But beneath the surface, those bones can become brittle and prone to unusual fractures, especially in the femur or jaw.
Another class of drugs, like Prolia (denosumab), takes a different approach by targeting the cells that break down bone. While initial results seem promising, stopping the drug can cause a rebound effect, leading to rapid bone loss and increased fracture risk. It’s a dangerous cycle: a treatment that creates dependency.
Bone is a living tissue that responds to stress and use. When muscles pull on bones during movement, especially weight-bearing exercise, bones adapt by becoming stronger. This is the foundation of true bone strength.
Meanwhile, nutrients like calcium, magnesium, vitamin D, and K2 play vital roles in supporting bone health. But so do hormones, especially estrogen and testosterone. Lifestyle, inflammation, diet, stress, and gut health also shape how our bones respond and repair over time.
So why aren’t these factors the focus of osteoporosis care? Because they don’t generate billions in revenue.
When patients start these medications, they’re rarely told about the risks: spontaneous femur fractures, osteonecrosis of the jaw, intense muscle pain, and more. These complications are real—and in some cases, devastating. Yet once someone begins treatment, stopping isn’t easy. Withdrawal effects and fear of fracture often keep patients locked in.
This is the quiet cost of overmedicalizing a condition that should be approached with nuance. Instead of empowering people with knowledge, the system pushes pills and scans.
Drug trials often manipulate data to make outcomes look more favorable. For example, studies will report “relative risk reduction” rather than “absolute risk.” That makes small benefits appear dramatic. A fracture rate going from 2% to 1% may be called a 50% risk reduction, when in reality, 98 out of 100 people would have been fine either way.
This kind of statistical sleight-of-hand is common in osteoporosis drug research. And patients are the ones misled by it.
Osteoporosis is not just about numbers. It’s about biology, lifestyle, and real-world outcomes. Preventing fractures means more than manipulating bone density—it means improving balance, strength, coordination, and addressing root causes of poor bone metabolism.
A truly informed approach would prioritize muscle mass, mobility, nutrient status, and hormone balance. It would stop scaring people into long-term drug dependency and start teaching them how to build real resilience.
The story of osteoporosis is not about lack of treatment. It’s about lack of truth. Patients are handed fear-based prescriptions without understanding what those treatments do—or what they hide.
GoldCare was created to break that cycle. We are building a movement rooted in facts, not pharma profits. Our members get access to uncensored information, doctors who think critically, and a platform that promotes genuine health, not just numbers on a chart.
This is about reclaiming power. About ending dependency. About finally hearing what the system refuses to say.
Become a GoldCare member now. Stop relying on the system that sells silence, and start building strength from real knowledge. Click here.
Disclaimer: This content is not medical advice. For personalized guidance, please consult a GoldCare provider.
Reference:“What We Aren’t Told About Osteoporosis.” Published by The Forgotten Side of Medicine (Midwestern Doctor Substack). Available at: What We Aren’t Told About Osteoporosis
.png)
.png)
.png)
%20blog.png)
.png)
.png)
%20(3).jpg)
%20(2).jpg)
%20(1)%20(1).jpg)
.jpg)
%20(1).jpg)
.jpg)
.png)
.jpeg)
.jpeg)
